|
WO2001070677A1
(en)
*
|
2000-03-20 |
2001-09-27 |
Merck Sharp & Dohme Limited |
Sulphonamido-substituted bridged bicycloalkyl derivatives
|
|
GB0209991D0
(en)
*
|
2002-05-01 |
2002-06-12 |
Merck Sharp & Dohme |
Therapeutic agents
|
|
GB0209997D0
(en)
|
2002-05-01 |
2002-06-12 |
Merck Sharp & Dohme |
Therapeutic agents
|
|
GB0209995D0
(en)
*
|
2002-05-01 |
2002-06-12 |
Merck Sharp & Dohme |
Therapeutic agents
|
|
DE60328182D1
(de)
|
2002-05-01 |
2009-08-13 |
Merck Sharp & Dohme |
Heteroaryl substituierte spirocyclische sulfamide zur hemmung von gamma sekretase
|
|
GB0225474D0
(en)
|
2002-11-01 |
2002-12-11 |
Merck Sharp & Dohme |
Therapeutic agents
|
|
GB0225475D0
(en)
*
|
2002-11-01 |
2002-12-11 |
Merck Sharp & Dohme |
Therapeutic agents
|
|
US7521481B2
(en)
|
2003-02-27 |
2009-04-21 |
Mclaurin Joanne |
Methods of preventing, treating and diagnosing disorders of protein aggregation
|
|
EP1638951B1
(en)
|
2003-05-16 |
2008-02-13 |
MERCK SHARP & DOHME LTD. |
Cyclohexyl sulphones as gamma-secretase inhibitors
|
|
GB0318447D0
(en)
*
|
2003-08-05 |
2003-09-10 |
Merck Sharp & Dohme |
Therapeutic agents
|
|
EP1667984B1
(en)
*
|
2003-09-24 |
2011-05-18 |
Merck Sharp & Dohme Ltd. |
Gamma-secretase inhibitors
|
|
GB0326039D0
(en)
|
2003-11-07 |
2003-12-10 |
Merck Sharp & Dohme |
Therapeutic agents
|
|
AU2005236063A1
(en)
*
|
2004-04-20 |
2005-11-03 |
Merck & Co., Inc. |
2, 4, 6-substituted pyridyl derivative compounds useful as beta-secretase inhibitors for the treatment of Alzheimer's disease
|
|
WO2006123182A2
(en)
|
2005-05-17 |
2006-11-23 |
Merck Sharp & Dohme Limited |
Cyclohexyl sulphones for treatment of cancer
|
|
WO2006123185A2
(en)
|
2005-05-19 |
2006-11-23 |
Merck Sharp & Dohme Limited |
Sulphamides for treatment of cancer
|
|
CA2644136A1
(en)
|
2006-02-27 |
2007-09-07 |
The Johns Hopkins University |
Cancer treatment with gamma-secretase inhibitors
|
|
EP2089383B1
(en)
|
2006-11-09 |
2015-09-16 |
Probiodrug AG |
3-hydr0xy-1,5-dihydr0-pyrr0l-2-one derivatives as inhibitors of glutaminyl cyclase for the treatment of ulcer, cancer and other diseases
|
|
EP2094836B1
(en)
|
2006-11-15 |
2016-06-08 |
Massachusetts Eye & Ear Infirmary |
Generation of inner ear cells
|
|
US9126987B2
(en)
|
2006-11-30 |
2015-09-08 |
Probiodrug Ag |
Inhibitors of glutaminyl cyclase
|
|
CA2676715A1
(en)
|
2007-02-12 |
2008-08-21 |
Merck & Co., Inc. |
Piperazine derivatives for treatment of ad and related conditions
|
|
AU2008220785B2
(en)
|
2007-03-01 |
2013-02-21 |
Vivoryon Therapeutics N.V. |
New use of glutaminyl cyclase inhibitors
|
|
WO2008108445A1
(ja)
|
2007-03-07 |
2008-09-12 |
Takeda Pharmaceutical Company Limited |
ベンゾオキサゼピン誘導体およびその用途
|
|
JP5667440B2
(ja)
|
2007-04-18 |
2015-02-12 |
プロビオドルグ エージー |
グルタミニルシクラーゼ阻害剤としてのチオ尿素誘導体
|
|
US8377886B2
(en)
*
|
2007-09-14 |
2013-02-19 |
Albert Einstein College Of Medicine Of Yeshiva University |
Use of gamma secretase inhibitors and notch pathway inhibitors for treatment and prevention of renal disease
|
|
KR101595238B1
(ko)
|
2007-12-21 |
2016-02-18 |
리간드 파마슈티칼스 인코포레이티드 |
선택적 안드로겐 수용체 조절제(ｓａｒｍ) 및 이의 용도
|
|
WO2009128057A2
(en)
|
2008-04-18 |
2009-10-22 |
UNIVERSITY COLLEGE DUBLIN, NATIONAL UNIVERSITY OF IRELAND, DUBLIN et al |
Psycho-pharmaceuticals
|
|
WO2010060088A2
(en)
|
2008-11-24 |
2010-05-27 |
Massachusetts Eye & Ear Infirmary |
Pathways to generate hair cells
|
|
WO2010114780A1
(en)
|
2009-04-01 |
2010-10-07 |
Merck Sharp & Dohme Corp. |
Inhibitors of akt activity
|
|
JP5934645B2
(ja)
|
2009-09-11 |
2016-06-15 |
プロビオドルグ エージー |
グルタミニルシクラーゼ阻害剤としてのヘテロ環式誘導体
|
|
US8859776B2
(en)
|
2009-10-14 |
2014-10-14 |
Merck Sharp & Dohme Corp. |
Substituted piperidines that increase p53 activity and the uses thereof
|
|
WO2011046774A1
(en)
*
|
2009-10-16 |
2011-04-21 |
Merck Sharp & Dohme Corp. |
Diaryl ether derivatives as notch sparing gamma secretase inhibitors
|
|
WO2011107530A2
(en)
|
2010-03-03 |
2011-09-09 |
Probiodrug Ag |
Novel inhibitors
|
|
JP5688745B2
(ja)
|
2010-03-10 |
2015-03-25 |
プロビオドルグ エージー |
グルタミニルシクラーゼ（ｑｃ、ｅｃ２．３．２．５）の複素環阻害剤
|
|
WO2011131748A2
(en)
|
2010-04-21 |
2011-10-27 |
Probiodrug Ag |
Novel inhibitors
|
|
US8999957B2
(en)
|
2010-06-24 |
2015-04-07 |
Merck Sharp & Dohme Corp. |
Heterocyclic compounds as ERK inhibitors
|
|
CA2805265A1
(en)
|
2010-08-02 |
2012-02-09 |
Merck Sharp & Dohme Corp. |
Rna interference mediated inhibition of catenin (cadherin-associated protein), beta 1 (ctnnb1) gene expression using short interfering nucleic acid (sina)
|
|
WO2012024170A2
(en)
|
2010-08-17 |
2012-02-23 |
Merck Sharp & Dohme Corp. |
RNA INTERFERENCE MEDIATED INHIBITION OF HEPATITIS B VIRUS (HBV) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
|
|
WO2012030685A2
(en)
|
2010-09-01 |
2012-03-08 |
Schering Corporation |
Indazole derivatives useful as erk inhibitors
|
|
US9242981B2
(en)
|
2010-09-16 |
2016-01-26 |
Merck Sharp & Dohme Corp. |
Fused pyrazole derivatives as novel ERK inhibitors
|
|
WO2012058210A1
(en)
|
2010-10-29 |
2012-05-03 |
Merck Sharp & Dohme Corp. |
RNA INTERFERENCE MEDIATED INHIBITION OF GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACIDS (siNA)
|
|
EP2654748B1
(en)
|
2010-12-21 |
2016-07-27 |
Merck Sharp & Dohme Corp. |
Indazole derivatives useful as erk inhibitors
|
|
EP2686313B1
(en)
|
2011-03-16 |
2016-02-03 |
Probiodrug AG |
Benzimidazole derivatives as inhibitors of glutaminyl cyclase
|
|
ES2389416B1
(es)
*
|
2011-03-30 |
2013-09-16 |
Fundación Instituto Mediterraneo Para El Avance De La Biotecnología Y La Investigación Sanitaria (Imabis) |
Uso de derivados de sulfamidas como neuroprotectores.
|
|
WO2013016411A1
(en)
*
|
2011-07-28 |
2013-01-31 |
Garry Robert Smith |
Novel fluorinated cyclic sulfamides exhibiting neuroprotective action and their method of use
|
|
EP2770987B1
(en)
|
2011-10-27 |
2018-04-04 |
Merck Sharp & Dohme Corp. |
Novel compounds that are erk inhibitors
|
|
WO2013165816A2
(en)
|
2012-05-02 |
2013-11-07 |
Merck Sharp & Dohme Corp. |
SHORT INTERFERING NUCLEIC ACID (siNA) COMPOSITIONS
|
|
CA2883896C
(en)
|
2012-09-07 |
2023-03-07 |
Massachusetts Eye & Ear Infirmary |
Treating hearing loss
|
|
CA2884309A1
(en)
|
2012-09-07 |
2014-03-13 |
Massachusetts Eye And Ear Infirmary |
Methods and compositions for regenerating hair cells and/or supporting cells from differentiated cochlear cells or differentiated utricular cells by modulation of notch and cmyc activity
|
|
WO2014052563A2
(en)
|
2012-09-28 |
2014-04-03 |
Merck Sharp & Dohme Corp. |
Novel compounds that are erk inhibitors
|
|
ME02925B
(me)
|
2012-11-28 |
2018-04-20 |
Merck Sharp & Dohme |
Kompozicije i postupci za liječenje kancera
|
|
TW201429969A
(zh)
|
2012-12-20 |
2014-08-01 |
Merck Sharp & Dohme |
作爲ｈｄｍ２抑制劑之經取代咪唑吡啶
|
|
WO2014120748A1
(en)
|
2013-01-30 |
2014-08-07 |
Merck Sharp & Dohme Corp. |
2,6,7,8 substituted purines as hdm2 inhibitors
|
|
US8859286B2
(en)
|
2013-03-14 |
2014-10-14 |
Viacyte, Inc. |
In vitro differentiation of pluripotent stem cells to pancreatic endoderm cells (PEC) and endocrine cells
|
|
US20160194368A1
(en)
|
2013-09-03 |
2016-07-07 |
Moderna Therapeutics, Inc. |
Circular polynucleotides
|
|
EP3094323A4
(en)
|
2014-01-17 |
2017-10-11 |
Ligand Pharmaceuticals Incorporated |
Methods and compositions for modulating hormone levels
|
|
CA2952315A1
(en)
|
2014-07-11 |
2016-01-14 |
Genentech, Inc. |
Notch pathway inhibition
|
|
WO2016022776A2
(en)
|
2014-08-06 |
2016-02-11 |
Massachusetts Eye And Ear Infirmary |
Increasing atoh1 life to drive sensorineural hair cell differentiantion
|
|
JP6676058B2
(ja)
|
2015-01-14 |
2020-04-08 |
ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ |
ヘテロアリーレン架橋したベンゾジアゼピン二量体、そのコンジュゲート、ならびに製造および使用方法
|
|
AU2016297793A1
(en)
|
2015-07-24 |
2018-02-08 |
Oncotracker, Inc. |
Gamma secretase modulators for the treatment of immune system dysfunction
|
|
WO2017096233A1
(en)
|
2015-12-04 |
2017-06-08 |
Massachusetts Eye And Ear Infirmary |
Treatment of hearing loss by inhibition of casein kinase 1
|
|
CN109219439B
(zh)
|
2016-01-29 |
2022-09-20 |
马萨诸塞眼科耳科诊所 |
内耳支持细胞的扩增和分化及其使用方法
|
|
JP6840774B2
(ja)
|
2016-05-16 |
2021-03-10 |
ザ ジェネラル ホスピタル コーポレイション |
肺上皮エンジニアリングにおけるヒト気道幹細胞
|
|
US10975084B2
(en)
|
2016-10-12 |
2021-04-13 |
Merck Sharp & Dohme Corp. |
KDM5 inhibitors
|
|
MX390370B
(es)
|
2016-12-16 |
2025-03-20 |
Pipeline Therapeutics Inc |
Metodos para tratar la sinaptopatia coclear
|
|
IL268349B2
(en)
|
2017-02-17 |
2024-08-01 |
Hutchinson Fred Cancer Res |
Combination therapies for treatment of bcma-related cancers and autoimmune disorders
|
|
ES2812698T3
(es)
|
2017-09-29 |
2021-03-18 |
Probiodrug Ag |
Inhibidores de glutaminil ciclasa
|
|
EP3706747B1
(en)
|
2017-11-08 |
2025-09-03 |
Merck Sharp & Dohme LLC |
Prmt5 inhibitors
|
|
US10947234B2
(en)
|
2017-11-08 |
2021-03-16 |
Merck Sharp & Dohme Corp. |
PRMT5 inhibitors
|
|
US11981701B2
(en)
|
2018-08-07 |
2024-05-14 |
Merck Sharp & Dohme Llc |
PRMT5 inhibitors
|
|
EP3833669A4
(en)
|
2018-08-07 |
2022-05-11 |
Merck Sharp & Dohme Corp. |
PRMT5 INHIBITORS
|
|
WO2020033282A1
(en)
|
2018-08-07 |
2020-02-13 |
Merck Sharp & Dohme Corp. |
Prmt5 inhibitors
|
|
WO2020033288A1
(en)
|
2018-08-07 |
2020-02-13 |
Merck Sharp & Dohme Corp. |
Prmt5 inhibitors
|
|
AU2020257397B2
(en)
|
2019-04-19 |
2026-02-26 |
Ligand Pharmaceuticals Inc. |
Crystalline forms and methods of producing crystalline forms of a compound
|
|
EP4076460B1
(en)
|
2019-12-17 |
2026-01-21 |
Merck Sharp & Dohme LLC |
1,4-dihydro-2h-spiro[isoquinoline-3,4'-piperidine derivatives as prmt5 inhibitors for the treatment of cancer
|
|
CN115003303B
(zh)
|
2019-12-17 |
2024-03-08 |
默沙东公司 |
Prmt5抑制剂
|
|
US12595248B2
(en)
|
2019-12-17 |
2026-04-07 |
Merck Sharp & Dohme Llc |
PRMT5 inhibitors
|
|
JP7589247B2
(ja)
|
2019-12-17 |
2024-11-25 |
メルク・シャープ・アンド・ドーム・エルエルシー |
Ｐｒｍｔ５阻害剤
|
|
BR112022018987A2
(pt)
|
2020-03-26 |
2022-11-01 |
Seagen Inc |
Métodos de tratamento de mieloma múltiplo
|
|
JP2025511436A
(ja)
|
2022-09-02 |
2025-04-16 |
メルク・シャープ・アンド・ドーム・エルエルシー |
エキサテカン由来トポイソメラーゼ－１阻害薬医薬組成物及びその使用
|
|
CN120417935A
(zh)
|
2022-10-25 |
2025-08-01 |
默沙东有限责任公司 |
依喜替康衍生的adc接头-载荷及其药物组合物和用途
|
|
US20240207425A1
(en)
|
2022-12-14 |
2024-06-27 |
Merck Sharp & Dohme Llc |
Auristatin linker-payloads, pharmaceutical compositions, and uses thereof
|